Introduction
Preeclampsia is a multi-system pregnancy-specific disease which affects 2 to 8% of all pregnancies. 1 It is characterized by placental and maternal vascular dysfunction. It is one of the leading cause of both maternal and fetal morbidity and as well as their mortality in the developing world. 2 There is need to balance the risks between maternal and perinatal outcomes, as expectant management improves neonatal outcome, but at the same time worsens maternal conditions. 3,4,5. Clinical diagnosis of preeclampsia in late stages gives very little scope for expectant management. 6 Hence a pre-clinical diagnostic test which is able to predict pre eclampsia and its severity is needed. Evaluation of bio-markers and imaging techniques has shown that none have adequate sensitivity and specificity or the convenience for prediction or diagnosis of pre eclampsia but they help only in diagnosis of advanced disease with established end organ damages.
In the development of placenta, there is invasion of the cytotrophoblasts into the maternal spiral arterioles and the small caliber resistance vessels are transformed to high caliber conduit vessels. This is one of the early steps in placental development which starts from first trimester (10-12 weeks) and continues till 18 to 20 weeks of gestation. The two main components in the pathogenesis of pre eclampsia are the abnormal placentation and endothelial dysfunction. Abnormal placentation is often quoted as cause of pre eclampsia rather than the fetus. Symptoms of pre eclampsia persisted until the delivery of the placenta even in rare cases of extra uterine pregnancies. This brings to light the fact that the presence of fetus is not necessary for the development of pre eclampsia. 7 The process of normal placental invasion by the cytotrophoblasts fails in pre eclampsia, leading to a shallow invasion of the spiral arterioles keeping them as small caliber resistance vessel leading to defective uteroplacental circulation and worsening placental perfusion. 7, 8 Placental growth factor (PlGF) belongs to the VEGF (vascular endothelial growth factor) sub-family and it has a key role in angiogenesis and vasculogenesis. It is abundantly seen in placental trophoblast and also in villous trophoblast, in addition to other tissues. In normal pregnancy the expression of PlGF protein and its mRNA are markedly increased during the second trimester. There is detachment of these syncytial knots from the syncytiotrophoblast, which form metabolically active multinucleated aggregates loaded with sFlt1 protein and mRNA which are accelerated in preeclampsia contributing to the maternal vascular injury. PlGF synthesized by syncytiotropoblast increases with gestataional age reaching peak by 26 to 30 weeks of gestation and declines towards term. 9 PlGF is very much lowered in pre eclampsia and it has been proved that PlGF values are markedly lowered 5 weeks before the onset of pre eclampsia which assures us of its predictive capabilities. 7 Levels of sFlt-1 are higher and PlGF lower in preeclamptic women, suggesting that it is mainly sourced from the placenta. 10 PlGF to sFlt-1 ratio has been proposed to be one among the best methods for predicting preeclampsia before the onset of the disease. 11, 12, 13 In pre eclamptic women, the PlGF levels were significantly lower not only in the plasma, but also in the urine. 14 Plasma PlGF in early second trimester could be an effective predictor of early onset preeclampsia in women who are overweight/obese pregnant than in wom men with normal BMI or those who are over weight. 15 Women who had pre eclampsia had significantly lower levels of PlGF where mean was 90 pg/ml in the pre eclamptic group as to 142 pg/ml in the control group. The maximum difference in the values of PlGF was noted in the weeks preceding pre eclampsia along with an increase in the sFlt-1 levels. The study conducted by Levine et al concluded that increased levels of sFlt-1 and reduced levels of PlGF is useful as a predictor for the subsequent development of preeclampsia. 
II. Aim Of The Study
The aims of study is to determine the diagnostic value of placental growth factor for predicting the occurrence of pre eclampsia in the gestational period from 24 to 30 weeks. To compare the value of placental growth factor in predicting mild or severe pre eclampsia. To determine the association of placental growth factor with variables such as blood pressure, BMI and fetal outcome.
III. Materials And Methodology
A prospective study was done in 80 randomly selected women who attended the casualty and antenatal OPD at the Institute of Obstetrics Gynecology, Chennai during the period from August 2014 to June 2015. The study protocol was approved by the Institutional ethical committee. The inclusion criteria were: (1) Pregnant mothers between 24 and 30 weeks of gestation (2) Randomly selected population (3) Antenatal mothers who were willing to deliver in our institution.
The exclusion criteria were: (1) Diagnosed preeclampsia (2) Chronic hypertension (3) Multiple Gestation (4) Patient not willing to participate in the study Informed and written consent for the study was obtained from all patients. History was taken in detail and patients were subjected to clinical examination. Venous blood samples of 2.5ml with EDTA were collected from randomly selected pregnant mothers between 24 and 30 weeks to determine PlGF values by fluorescent immunoassay method. PlGF values are expressed in pg/ml. The collected data were analyzed using appropriate statistical methods. All antenatal mothers who were included in the study were followed up through admission, delivery and the immediate post-partum period. The sensitivity and specificity are 80.95% and 89.83% respectively, for PlGF criteria of ≤ 350.
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Of the 80 study patients, 14 (17.5%) had previous history of pre eclampsia and 10 (71.4%) among those with previous history of pre eclampsia, developed subsequent pre eclampsia. So there is a statistically significant association between previous history of pre eclampsia and subsequent preeclampsia in our study.
Distribution of gestational age at which pregnancy was terminated in Normotensive mothers compared with preeclamptic mothers is shown in bar diagram below
FIGURE-VI
The blue bars represent those without pre eclampsia and the green bar represents the pre eclamptic patients. Pre eclamptic patients had pregnancies terminated at earlier gestational age compared to those who were normal and carried it to term. The patients who developed severe pre eclampsia terminated by 32weeeks (n=6 ; 28.6%) where as the those who had mild pre eclampsiacarried their pregnancy till 37 weeks,(n=6 ; 28.6% ). More severe the degree of pre eclampsia the earlier the pregnancy was terminated. distribution of gestational age at which pregnancy was terminated FIGURE-VII
TAB LE-IV Anova Pregnancy Terminated at Gestational Age
Of the 80 patients, 47 delivered at term (58.75%), 33 delivered preterm (41.25%). 3 patients had pregnancy terminated within 2 weeks of detecting low PlGF value. Out of the 3 patients, 2 had severe pre eclampsia, all 3 patients were 2 nd gravida, all 3 underwent cesarean sections.2 out of the 3 babies showed features of IUGR.2 out of the 3 patients had previous history of pre eclampsia. In this study, Youden index is 
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IV. Discussion
Serum PlGF in early second trimester could be an effective predictor of early onset preeclampsia in women who are overweight/obese pregnant than in women with normal BMI or who are underweight 15 , our study correlates with this study by Ghosh et al.
In his study Akolekar concluded that a combination of maternal characteristics including the obstetric history, uterine artery PI and maternal serum PlGF taken between 11 and 13 weeks would prove to be an effective screening tool for patients suspected to develop pre eclampsia later on in their pregnancy. 16 Pre eclampsia had an increased incidence of 3.2 times that of the control group with confidence interval of 95%,and the mean PlGF value was 62.5 pg/ml in pre eclamptic individuals. This study by Necmiye Dover concluded that low PlGF values in the second trimester have increased risk of developing pre eclampsia. 17 Our study correlates well with this finding Chikako Hirashima,in his study concluded that the values of PlGF or the sFlt-1/PlGF ratio appears to be clinically useful in the second trimester and also useful in the prediction of early onset pre eclampsia .In the early third trimester the combination of angiogenesis-related factors and other risk factors yielded the best LR+. 18 Further studies are needed to confirm the findings and in combination may be a better predictor of pre eclampsia. Bolin et al has reviewed articles and has stated that in the first trimester, maternal characteristics such as mean arterial pressure, uterine artery pulsatility index and the biochemical markers PAPP-A and PlGF is of predictive value with 95% specificity and 93% sensitivity for early-onset and 36 % for late-onset preeclampsia. 19 The threshold value of PlGF at which a women would develop pre eclampsia, has not been clearly defined among the Indian population which once again states the need for more work on this accurate predictive test in order to individualize the level of surveillance during pregnancy.
V. Conclusion
Placental Growth Factor (PlGF) levels were significantly lower in patients prone to develop pre eclampsia. It also helps in risk stratification of pre eclamptic patients, as mild and severe pre eclampsia thereby early detection and appropriate management is possible in these patients. Studies with larger population size are needed in our setting to further define the diagnostic accuracy and predictive capabilities of the various angiogenic markers.
